Valuation: Pharmadrug Inc.

Market Cap 7L 5L 4L 4L 4L 4.55Cr 7L 47.55L 18.79L 2.38Cr 17.98L 17.6L 7.51Cr P/E 2024
-1.31x
P/E 2025 -4.23x
Enterprise Value 21.72L 15.5L 13.85L 12.79L 11.6L 15Cr 22.07L 1.54Cr 60.81L 7.71Cr 58.2L 56.97L 24Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.22%
Yield 2024 *
-
Yield 2025 -
3 months-50.00%
6 months-50.00%
Current year-66.67%
1 week 0
Extreme 0.005
0
1 month 0
Extreme 0.005
0.01
Current year 0
Extreme 0.005
0.02
1 year 0
Extreme 0.005
0.02
3 years 0
Extreme 0.005
0.08
5 years 0
Extreme 0.005
0.46
10 years 0
Extreme 0.005
4.55
Manager TitleAgeSince
Director of Finance/CFO 50 20/10/2023
Director TitleAgeSince
Director/Board Member 82 20/12/2016
Chairman - 27/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Other

Chairman

13,80,000 1.2929%
03/05/24 Other

Director

0 0%
03/05/24 Option

Director

5,00,000 0.5718%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-85.71% 5L
-2.54%+1.75%+56.75%+117.82% 1,16500Cr
-1.42%+4.16%+36.73%+72.42% 64TCr
+0.16%+0.79%+24.91%+95.34% 50TCr
-0.31%+2.95%+39.36%+63.56% 38TCr
-1.34%+0.06%+65.81%+41.49% 36TCr
-0.68%+1.67%+22.07%+50.94% 30TCr
-1.20%+0.99%+2.26%+22.95% 27TCr
-1.79%+1.20%+48.41%+57.55% 24TCr
-0.73%-0.85%+28.47%+100.57% 19TCr
Average -0.57%+2.29%+27.48%+53.69% 40.55TCr
Weighted average by Cap. -0.20%+3.17%+40.78%+80.33%

Financials

2024 2025
Net sales - -
Net income -8L -6L -5L -5L -4L -5.38Cr -8L -56.21L -22.21L -2.81Cr -21.26L -20.81L -8.88Cr -4L -3L -2L -2L -2L -2.6Cr -4L -27.17L -10.73L -1.36Cr -10.27L -10.06L -4.29Cr
Net Debt 12.74L 9L 8L 8L 7L 8.63Cr 12.94L 90.27L 35.67L 4.52Cr 34.14L 33.41L 14Cr 15.01L 10.71L 10L 9L 8L 10Cr 15.25L 1.06Cr 42.02L 5.33Cr 40.22L 39.37L 17Cr
Projected Income Statement - Annual - Pharmadrug Inc.
Logo Pharmadrug Inc.
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. It also owns 100% of SecureDose Synthetics Inc. a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.
Employees
-
Date Price Change Volume
23/26/23 CA$0.005000 0.00% 7,000
22/26/22 CA$0.005000 0.00% 5,000
21/26/21 CA$0.005000 0.00% 20,682
20/26/20 CA$0.005000 0.00% 1,035
19/26/19 CA$0.005000 0.00% 3,464
  1. Stock Market
  2. Stocks
  3. PHRX Stock